Loading clinical trials...
Loading clinical trials...
A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
Conditions
Interventions
ARGX-110
AZA
Locations
7
France
Marseille, France
Paris, France
Pierre-Bénite, France
Toulouse, France
Aarau, Switzerland
Bern, Switzerland
Start Date
December 1, 2016
Primary Completion Date
August 1, 2022
Completion Date
August 1, 2022
Last Updated
August 9, 2023
NCT06852222
NCT07270978
NCT05292664
NCT06499285
NCT04953897
NCT04953910
Lead Sponsor
OncoVerity, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions